ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) saw a significant drop in short interest in January. As of January 31st, there was short interest totalling 16,230,000 shares, a drop of 5.2 ...

ACAD's Other Pipeline Goals for 2025-2026 We note that Acadia’s first drug, Nuplazid (pimavanserin), is approved in the United States for the treatment of hallucinations and delusions associated ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Morgan Stanley analyst Jeffrey Hung maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of ...

W W King and Newberry Acad will take the court on Tuesday, Feb. 4 at 6:30 p.m. ET. Don't miss out on any of the action with ...

Deutsche Bank initiated coverage of Acadia Pharmaceuticals (ACAD) with a Hold rating and $22 price target Maximize Your Portfolio with Data ...